Alberto Montero, MD, MBA, CPHQ, explains the rationale for evaluating zanidatamab plus evorpacept in HER2-expressing metastatic breast cancer.
Alberto Montero, MD, MBA, CPHQ
Advertisement
Alberto Montero, MD, MBA, CPHQ, is a clinical director of the Breast Cancer Program at University Hospitals, medical director of the Clinical Trials Unit at Seidman Cancer Center, and professor of Medicine at Case Western Reserve University, all in Cleveland, Ohio.
Articles by Alberto Montero, MD, MBA, CPHQ
Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.
Alberto Montero, MD, MBA, CPHQ, discusses data with the combination of zanidatamab and evorpacept in HER2-positive and HER2-low metastatic breast cancer.
Alberto Montero, MD, MBA, CPHQ, discusses the mechanism of action and potential advantages of the mutant-selective PI3Kα inhibitor STX-478 in solid tumors.
Alberto Montero, MD, MBA, CPHQ, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.
Advertisement
Latest Updated Articles
Dr Montero on the Rationale for Evaluating Zanidatamab/Evorpacept in HER2+ Metastatic Breast CancerPublished: March 18th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant
4
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
5